Diagnostic usefulness of tumor markers in the thyroid cytological samples extracted by fine-needle aspiration biopsy

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 10, Issue 1, 2010, Pages 47-56

  Manuel, José ^a   Sáaez, Gómez ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Fine needle aspiration biopsy; Galectin 3; Gene therapy; Telomerase; Thyroglobulin; Thyroid peroxidase

Indexed keywords

BETA CATENIN; CAVEOLIN; CYCLOOXYGENASE 2; CYTOKERATIN; DIPEPTIDYL PEPTIDASE IV; ENDOTHELIAL CELL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FIBRONECTIN; GALECTIN 1; GALECTIN 3; GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; LACTOFERRIN; LAMININ; ONCOPROTEIN; PROTEIN KINASE C; PROTEIN P53; PROTEIN P63; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RECOMBINANT PROTEIN; SOMATOSTATIN RECEPTOR; TELOMERASE; THYROGLOBULIN; THYROID PEROXIDASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNINDEXED DRUG; UVOMORULIN;

ASPIRATION BIOPSY; CANCER GENE THERAPY; CLINICAL PRACTICE; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DNA SEQUENCE; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; HUMAN; NONHUMAN; PRACTICE GUIDELINE; PROTEIN FUNCTION; REVIEW; THYROID ADENOMA; THYROID GLAND; THYROID HYPERPLASIA; THYROID TUMOR; TUMOR CELL;

EID: 77950831042     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153010790828000     Document Type: Review

References (88)

1. Gómez, J.M.; Gómez, N.; Sahún, M.; Rafecas, A.; Villabona, C. and Soler, J. (1997) Validity of risk group definition in differentiated thyroid carcinoma. End. Rel. Cancer, 4, 459-464.
2. Cooper, D.S.; Doherty, G.M.; Haugen, B.R.; Kloos, R.T.; Lee, S.L.; Mandel, S.L.; Mazzaferri, E.L.; McIver, B.; Sherman, S.I.; Tuttle, R.M. and the American Thyroid Association GuidelinesTaskforce. (2006) Management guidelines for patients with thyroidnodules and differentiated thyroid cancer. Thyroid, 16, 1-33.
3. Pacini, F.; Schlumberger, M.; Dralle, H.; Elisei, R.; Wiersinga, W.and the European Thyroid Cancer Taskforce. (2006) European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium. Eur. J. Endocrinol., 154, 787-903.
4. Haugen, B.R.; Woodmansee, W.W. and McDermott, M.T. (2002) Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumors. Clin. Endocrinol. (Oxf)., 56, 281-290.
5. Sahin, M.; Gursoy, A.; Tutuncu, N.B. and Guvener, D.N. (2006)Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules. Clin. Endocrinol. (Oxf)., 65, 514-518
6. Letsas, K.P.; Andrikoula, M. and Tsatsoulis, A. (2006) Fine needle aspiration biopsy-RT-PCR molecular analysis of thyroid nodules: to useful preoperative diagnostic tool. Minerva Endocrinol., 31, 179-182.
7. Murakawa, T.; Tsuda, H.; Tanimoto, T.; Tanabe, T.; Kitahara, S.and Matsubara, O. (2005) Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for to new therapeutic approach. Pathol. Intern., 55,757-765.
8. Kebebew, E.; Peng, M.; Reiff, E.; Duh, Q.-Y.; Clark, O.H. and McMillan, A. (2005) ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann. Surg., 242, 353-363.
9. Fryknä.s, M.; Wickenberg-Bolin, U.; Göransson, H.; Gustafsson, M.G.; Foukakis, T.; Lee, J.-J.; Ladegren, U.; Höög, A.; Larsson, C.; Grimelius, L.; Wallin, G.; Pettersson, U. and Isaksson, A. (2006) Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumor Biol., 27, 211-220.
10. Handle, S.L. (2005) The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid. Endocr. Pathol., 16, 295-309.
11. Segev, D.L.; Clark, D.P.; Zeiger, M.A. and Umbricht, C. (2003) Beyond the suspicious thyroid fine needle aspirate. Acta Cytol., 47,709-722.
12. Hewnry, J.F.; Denizot, A.; Porcelli, A.; Villafane, M.; Zoro, P. and Garcia, S. (1994) Thyroperoxidase immunodetection for the diagnosis of malignancy on fine-needle aspiration of thyroid nodules.World J. Surg., 18, 529-534.
13. de Micco, C.; Vassko, V. and Henry, J.F. (1999) The value of thyroid peroxidase immunochemistry for preoperative fine-needle aspiration diagnosis of the follicular variant of papillary thyroid cancer. Surgery, 12, 1200-1204.
14. Savin, S.; Cvejic, D.; Isic, T.; Paunovic, I.; Tatic, S. and Havelka,M. (2006) The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma. Exp. Oncol., 28, 70-74.
15. de Micco, C.; Savchenko, V.; Giorgi, R.; Sebag, F. and Henry, J.F. (2008) Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidaseIV. Br. J. Cancer, 98, 818-823.
16. Yousaf, U.; Christensen, L.H.; Rasmussen, A.K.; Jensen, F.; Mollerup, C.L.; Kirkegaard, J.; Lausen, I.; Rank, F. and Feldt-Rasmussen, U. (2008) Immunohistochemical staining for thyroidperoxidase (TPO) of needle core biopsies in the diagnosis of Scintigr phically cold thyroid nodules. Clin. Endocrinol. (Oxf)., 68, 996-1001.
17. Sigstad, E.; Heilo, A.; Paus, E.; Holgersen, K.; Grøholt, K.K.; Jørgensen, L.H.; Bogsrud, T.V.; Berner, A. and Bjoo, T. (2007) The usefulness of detecting thyroglobulin in fine-needle aspirates from patients with neck lesions using a sensitive thyroglobulin assay. Diagn. Cytopathol., 35, 761-767.
18. Kogan, E.A.; Rozhkova, E.B.; Seredin, V.P. and Paltsev, M.A. (2006) Prognostic value of the expression of thyroglobulin and oncomarkers (p53, EGFR, ret-oncogene) in different types of papillary carcinoma of the thyroid: clinicomorphological and immunohistochemicalstudies. Arkh Patol., 68, 8-11.
19. Boi, F.; Baghino, F.; Atzeni, F.; Lai, M.L.; Faa, L. and Mariotti, S. (2006) The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout flow from fine-needle aspiration biopsy of neck lymph nodes is maintainedin the presence of circulating anti-Tg antibodies. J. Clin. Endocrinol. Metab., 91, 1364-1369.
20. Cunha, N.; Rodrigues, F.; Curadeo F.; Ilhéau, O.; Cruz, C.;Naidenov, P.; Rascao, M.J.; Ganho, J.; Gomes, I.; Pereira, H.; Real, O.; Figueiredo, P.; Campos, B. and Valido F. (2007) Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: techniquefor the diagnosis of metastatic differentiated thyroid cancer. Eur. J. Endocrinol., 157, 101-107.
21. Baloch, Z.W.; Barroeta, J.E.; Walsh, J.; Gupta, P.K.; Livolsi, V.A.and Lange, R.J.E. (2008) The National Cancer Institute Thyroid fine needle aspiration state of science conference: a summation.Cytojournal., 5, 6.
22. Rossi, E.D.; Raffaelli, M.; Mulè, A.; Zannoni, G.F.; Pontecorvi, A.; Santeusanio, G.; Minimo, C. and Fadda, G. (2008) Relevance of immunocytochemistry on thin-layer cytology in thyroid lesions suspicious for medullary carcinoma: a case-control study. Appl.Immunohistochem. Mol. Morphol., 16, 548-553.
23. Wagner, K.; Arciaga, R.; Siperstein, A.; Milas, M.; Warshawsky, I.; Sethu, S.; Reddy, K. and Gupta, M.K. (2005) Thyrotropin receptor/ thyroglobulin messenger ribonucleic acid in peripheral blood and fine-needle aspiration cytology: diagnosis synergy for detecting thyroid cancer. J. Clin. Endocrinol. Metab., 90, 1921-1924.
24. Snozek, C.L.; Chambers, E.P.; Reading, C.C.; Sebo, T.J.; Sistrunk, J.W.; Singh, R.J. and Grebe, S.K. (2007) Serum thyroglobulin,high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J. Clin. Endocrinol. Metab., 92, 4278-4281.
25. Véaliz, J.; Brantes, S.; Ramos, C.; Aguayo, J.; Cáaceres, E.; Herrera, M.; Barbber, A.; Barria, M. and Wohlk, N. (2008) Thyroglobulin levels in needle lymph node cytology for the detection of papillary thyroid cancer recurrence. Rev. Med. Chil., 136, 1107-1112.
26. Wang, S.L.; Chen, W.T.; Wu, M.T.; Chan, H.M.; Yang, S.F. and Chai, C.Y. (2005) Expression of human telomerase to review transcriptase in thyroid follicular neoplasms: an immunohistochemical study. Endocr. Pathol., 16, 211-218.
27. Lerma, E.; Moor, J. and the Thyroid Study Group. (2005) Telomeraseactivity in "suspicious" thyroid cancer. Cancer Cytophol., 105, 492-497.
28. Fernáandez, P.L.; Merino, M.J.; Gómez, M.; Campo, E.; Medina, T.; Castronovo, V.; Sanjuáan, X.; Cardesa, A.; Liu, F.Y. and Sobel, M.E. (1997) Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J. Pathol., 181, 80-86.
29. Collet, J.F.; Hurbain, I.; Prengel, C.; Utzmann, O.; Scetbon, F.; Beranaudin, J.F. and Fajac, A. (2005) Galectin-3 immunodetection in follicular thryoid neoplasms: prospective study on fine-needle aspiration samples. Br. J. Cancer, 93, 1175-1181.
30. Ito, Y.; Yoshida, H.; Tomoda, C.; Miya, A.; Kobayashi, K.; Matsuzuka, F.; Yasuoka, H.; Kakudo, K.; Inohara, H.; Kuma, K. and Miyauchi, A. (2005) Galectin-3 expression in follicular tumors: and immunohistochemical study of its uses a marker of follicular carcinoma. Pathology, 37, 296-298.
31. De Matos, P.; Ferreira, A.P.; de Oliveira, F.F.; Saaumpçao, L.V.M.; Metze, K. and Ward, L.S. (2005) Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaning in the diagnosis of thyroid malignancy. Histopathology, 47, 391-401.
32. Cvejic, D.; Savin, S.; Petrovic, I.; Selemetjev, S.; Paunovic, I.; Tatic, S.; and Havelka, M. (2005) Galectin-3, proliferating cell nuclear antigene (PCNA) expression in papillary thyroid carcinoma. Exp. Oncol., 27, 210-214.
33. Aron, M.; Kapila, K. and Verma, K. (2006) Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. Indian J. Pathol. Microbiol., 49, 376-380.
34. Rossi, E.D.; Rafaelli, M.; Mule, A.; Miraglia, A.; Lombardi, C.P.; Vecchio, F.M. and Fadda, G. (2006) Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.Histopathology, 48, 795-800.
35. Scognamiglio, T.; Hyjek, E.; Kao, J. and Chen, Y.T. (2006) Diagnostic usefulness of HBME1, galectin-3, CK19 and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am. J. Clin. Pathol., 126, 700-708.
36. Kim, M.J.; Kim, H.J.; Hong, S.J.; Shong, Y.K. and Gong, G. (2006) Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Acta Cytol., 50, 28-34.
37. Mehrotra, P.; Okpokam, A.; Bouhaidar, R.; Johnson, S.J.; Wilson, J.A.; Davis, B.R. and Lennart, T.W. (2004) Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.Histopathology, 45, 493-500.
38. Saussez, S.; Glinoer, D.; Chantrain, G.; Pattou, F.; Carnaille, B.; Andréa, S.; Gabius, H.J. and Laurent, G. (2008) Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid, 18, 705-712.
39. Sapio, M.R.; Guerra, A.; Posca, D.; Limone, P.P.; Deandrea, M.; Motta, M.; Troncone, G., Caleo, A.; Vallefuoco, P.; Rossi, G.; Fenzi, G. and Vitale, M. (2007) Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr. Relat. Cancer, 14, 1089-1097.
40. Ersoz, S.; Sert, H.; Yandi, M.; Erem, C.; Mungan, S.; Ersoz, H.O.; Cobanoglu, U. and Hacihasanoglu, A . (2008) The significance of galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology. Pathol. Oncol. Res., 14,457-460.
41. Franco, C.; Martínez, V.; Allamand, J.P.; Medina, F.; Glasinovic, A.; Osorio, M. and Schachter, D. (2009) Molecular markers inthyroid fine-needle aspiration biopsy: a prospective study. Appl. Immunohistochem. Mol. Morphol., 17, 211-215.
42. Cheung, C.C.; Carydis, B.; Ezzat, S.; Bedard, Y.C. and Handle, S.L. (2001) Analysis of RET/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J. Clin. Endocrinol. Metab., 86, 2187-2190.
43. Domingues, R.; Mendonça, E.; Sobrinho, L. and Bugalho, M.J.(2005) Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology,16, 27-31.
44. Sapio, M.R.; Posca, D.; Raggioli, A.; Guerra, A.; Marotta, V.; Deandrea, M.; Motta, M.; Limone, P.P.; Troncone, G.; Caleo, A.; Rossi, G.; Fenzi, G. and Vitale, V. (2007) Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin. Endocrinol.(Oxf)., 66, 678-683.
45. Pizzolanti, G.; Russo, L.; Richiusa, P.; Bronte, V.; Nuara, R.B.; Rodolico, V.; Amato, M.C.; Smeraldi, L.; Sisto, P.S.; Nucera, M.;Bommarito, A.; Citarrella, R.; Lo Coco, R.; Cabibi, D.; Lo Coco, A.; Frasca, F.; Gulotta, G.; Latteri, M.A.; Modica, G.; Galluzzo, A. and Gioradano, C. (2007) Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid, 17, 1109-1115.
46. McIver, B.; Grebe, S.K. and Eberhardt, N.L. (2004) The PAX-8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr. Drug Targets Immune Endocr. Metabol. Disord., 4, 221-234.
47. Dwight, T.; Thopp, M.R.; Foukakis, T.T.; Lui, W.O.; Wallin, G.; Höög, A.; Frissk, T.; Larsson, C. and Zedenius, J. (2003) Involvement of the PAX8/peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumors. J. Clin. Endocrinol.Metab., 88, 4440-4445.
48. Lacroix, L.; Mian, C.; Barrier, T.; Talbot, M.; Caillou, B.; Schlumberger,M. and Bidart, J.M. (2004) PAX8 and peroxisome proliferator- activated gamma receptor 1 gene expression status in benign and malignant thyroid tissues. Eur. J. Endocrinol., 151, 367-374.
49. Lui, W.-O.; Foukakis, T.; Lidéan, J.; Thoppe, S.R.; Dwight, T.; Höög, A.; Zedenius, J.; Wallin, G.; Reimers, M. and Larsson, C. (2005) Expression profiling reveals a distint transcription signature in follicular thyroid carcinomas with a PAX8-PPARγ fusion oncogene. Oncogene, 24, 1467-1476.
50. Nikiforova, M.N.; Lynch, R.A.; Biddinger, P.W.; Alexander, E.K.; Dorn, G.W.; Tallini, G.; Kroll, T.G. and Nikiforov, Y.E. (2003) RAS point mutation and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab., 88, 2318-2326.
51. Di Cristofaro, J.; Silvy, M.; Lanteaume, A.; Marcy, M.; Carayon, P.and De Micco, C. (2006) Expression of TPO mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of RET, BRAF, RAS and PAX8 genes. Endocr. Rel. Cancer, 13, 485-495.
52. Ito, Y.; Yoshida, H.; Tomoda, C.; Uruno, T.; Takamura, Y.; Miya, A.; Kobayashi, K.; Natsusuka, F.; Nakamura, Y.; Kakudo, K.; Kuma, K. and Miyauchi, A. (2005) Caveolin-1 and 14-3-3 sigma expression in follicular variant of thyroid papillary carcinoma. Pathol. Res. Pract., 201, 545-549.
53. Pickett, C.A.; Agoff, S.N.; Widman, T.J. and Bronner, M.P. (2005) Altered expression of cyclines and cell cycle inhibitors in papillarythyroid cancer: prognostic implications. Thyroid, 15, 461-473.
54. Ensinger, C.; Kresmer, R.; Prommegger, R.; Spizzo, G. and Schmid, K.W. (2006) EpCAM overexpression in thyroid carcinomas: to histopathological study of 121 cases. Immunother., 29, 569-573.
55. Chandan, V.S.; Faquin, W.C.; Wilbur, D.C. and Khurana, K.K. (2006) The role of immunolocalization of CD57 and GLUT-1 in cell blocs in fine-needle aspiration diagnosis of papillary thyroid carcinoma. Cancer Cytopathol., 108, 331-336.
56. Mehrotra, P.; Gonzáalez, M.A.; Johnson, S.J.; Coleman, N.; Wilson, J.A.; Davis, B.R. and Lennard, T.W. (2006) Mcm-2 and Ki-67 havelimited potential in preoperative diagnosis of thyroid malignancy. Laryngoscope, 116, 1434-1438.
57. Kebebew, E.; Peng, M,.; Reiff, E.; Duh, Q.Y.; Clark, O.H. and McMillan, A. (2005) ECM1 and TMPRSS4 are diagnostic markersof malignant thyroid neoplasms and improve the accuracy of fine eedle aspiration biopsy. Ann. Surg., 242, 353-363.
58. Cerutti, J.M.; Latini, F.R.M.; Nakabashi, C.; Delcelo, R.; Andrade, V.P.; Amadei, M.J.; Hojail, F.C.; Hollis, D.; Shoemaker, J. and Riggins, G.J. (2006) Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin. Cancer Res., 12, 3311-3318.
59. Finley, D.J.; Lubitz, C.C.; Wei, C.; Zhu, B. and Fahey, III T.J. (2005) Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. Thyroid, 15, 562-568.
60. Towers-Cabala, C.; Bibbo, M.; Panhoist-Santos, A.; Barazi, H.; Krutzsch, H.; Roberts, D.D. and Merino, M.J. Identification of new biomarkers and application in thyroid cytology. Acta Cytol. 50, 518-528.
61. Monia, B.P.; Johnston, J.F.; Geiger, T.; Muller, M. and Fabbro, D. (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-RAF kinase. Nat. Med., 2, 668-675.
62. Fagin, F.A. (2004) How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J. Endocrinol., 183, 249-256.
63. Klein, M.; Vignaud, J.; Hennequin.,V.; Toussaint, B.; Bresler, L.; Pléanat, F.; Leclère, J.; Duprez, A. and Weryha, G. (2001) Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab., 86, 656-658.
64. Carlomagno, F.; Vitagliano, D.; Guida, T.; Ciardiello, F.; Tortura, G.; Vecchio, G.; Ryan, A.J.; Fontanini, G.; Fusco, A. and Santoro, M. (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res., 62, 7284-7290.
65. Huang, S.M.; Lee, J.C.; Wu, T.J. and Chow, N.H. (2001) Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J. Surg., 25, 302-306.
66. Bauer, A.J.; Terrell, R.; Doniparthi, N.K.; Patel, A.; Tuttle, R.M.; Saji, M.; Ringel, M.D. and Francis, G.L. (2002) Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid, 12, 953-961.
67. Dowlati, A.; Robertson, K.; Cooney, M.; Petros, W.P.; Stratford, M.; Jesberger, J.; Rafie, N.; Ovemoyer, B.; Makkar, V.; Stambler, B.; Taylor, A.; Waas, J.; Lewin, J.S.; McCrae, K.R. and Remick, S.S. (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res., 62, 3408-3416.
68. Kaczirek, K.; Schindl, M.; Weinhä.usel, A.; Sheuba, C.; Passler, C.; Prager, G.; Raderer, M.; Hamilton, G.; Mittlböck, M.; Siegl, V.; Pfragner, R. and Niederle, B. (2004) Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab., 89, 2397-2401.
69. Dziba, J.M.; Marcinek, R.; Venkataraman, G.; Robinson, J.A. and Ain, K.B. (2002) Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid, 12, 1063-1070.
70. Ringel, M.D.; Haynre, N.; Saito, J.; Saunier, B.; Schuppert, F.; Burch, H.; Bernet, V.; Burman, K.D.; Kohn, L.D. and Saji, M. (2001) Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res., 1, 6105-6111.
71. Park, J.-W.; Wong, M.G.; Lobo, M.; Hyun, W.C.; Duh, Q.-Y. and Clark, O.H. (2003) Modulation of tumor necrosis factor-related apoptosis-inducing ligand-inducing apopotosis by chemotherapy in thyroid cancer lines. Thyroid, 13, 1103-1110.
72. Chen, G.G.; Liu, Z.M.; Vlantis, A.C.; Tse, G.M.; Leung, B.C. and van Hasselt, C.A. (2004) Heme oxygenase-1 protects against apoptosis induced by tumor necrosis factor-alpha and cycloheximide in papillary thyroid carcinoma cells. J. Cell Biochem., 15, 1246-1256.
73. Specht, M.C.; Tucker, O.N.; Hocever, M.; Gonzáalez, D.; Teng, L. and Fahey, III T.J. (2002) Cyclooxygenase-2 expression in thyroid nodules. J. Clin. Endocrinol. Metab., 87, 358-363.
74. Nagayama, Y.; Nishihara, E.; Namba, H.; Yokoi, H.; Hasegawa, M. and Mizoguchi, H. (2001) Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/IoxP system. Cancer Gene Ther., 8, 36-44.
75. Spitzweig, C. and Morris, J.C. (2004) Gene therapy for thyroid cancer: current status and future prospects. Thyroid, 14, 424-434.
76. Imanishi, R.; Ohtsuru, A.; Iwamatsu, M.; Iioka, T.; Namba, H.; Seto, S.; Yano, K. and Yamashita, S. (2002) A histone deacetylase inhibitor enhances killing on undifferentiated thyroid carcinoma cells by p53 gene therapy. J. Clin. Endocrinol. Metab., 87, 4821-4824.
77. Deosten, M.; Frilling, A.; Steiwe, T. and Pütze, B.M. (2002) A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RETS signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. Surgery, 132, 991-997.
78. Scala, P.; Portella, G.; Fedele, M.; Chiapoetta, G. and Fusco, A. (2000) Adenovirus-mediated suppression of HMGI (Y) protein synthesis as potential therapy of human malignant neoplasia. Proc. Natl. Acad. Sci. USA, 97, 4256-4261.
79. Zhang, R.; Straus, F.H. and DeGroot, L.J. (2002) Cell-specific viral gene therapy of a Hürthle cell tumor. J. Clin. Endocrinol. Metab., 87, 1407-1414.
80. Ye, C.; Feng, C.; Wang, S.; Liu, X.; Lin, Y. and Li, M. (2002) Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology, 143, 3522-3528.
81. Portella, G.; Pacelli, R.; Libertini, S.; Cella, L.; Vecchio, G.; Salvatore, M. and Fusco, A. (2003) ONYX-015 enhances radiationinduced death of human anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab., 88, 5027-5032.
82. Kurebayashi, J.; Otsuki, T.; Tanaka, K.; Yamamoto, Y.; Moriya, T. and Sonoo, H. (2003). Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2. Thyroid, 13, 249-258.
83. Lee, Y.J.; Chung, J.K.; Shin, J.H.; Kang, J.H.; Jeong, J.M.; Lee, D.S. and Lee, M.C. (2004) In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid, 14, 889-895.
84. Smit, J.W.; Schroder-Van der Elst, J.P.; Karperien, M.; Que, I.; Stokkel, M. and van der Heide, D. (2003) Iodide kinetics and experimental (131) I therapy in a xenotransplanted human sodiumiodide symporter-transfected human follicular thyroid carcinoma cell line. J. Clin. Endocrinol. Metab., 87, 1247-1253.
85. Lee, W.W.; Lee, B.; Kim, S.J.; Jin, J.; Moon, D.H. and Lee, H. (2003) Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus. Oncol. Rep., 10, 845-849.
86. Lin, X.; Fisher, A.H.; Ryu, K.-Y.; Cho, J.-Y.; Sferra, T.J.; Kloos, R.T.; Mazzaferri, E.L. and Jhiang, S.M. (2004) Application of the Cre/Iox system to enhance thyroid targeted expression of sodium/iodide symporter. J. Clin. Endocrinol. Metab., 89, 2344-2350.
87. Haberkorn, U.; Altmann, A.; Jiang, S.; Morr, I.; Mahmut, M. and Eisenhut, M. (2001) Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene. Eur. J. Nucl. Med., 28, 633-638.
88. Cerrato, A.; De Falco, V. and Saantoro, M. (2009) Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J. Mol. Endocrinol., 43, 143-155.